A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Titre officiel

Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Sommaire:

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer (PC) and to use the variants reported to assess biomarker eligibility for niraparib interventional studies.

Description de l'essai

Primary Outcome:

  • Percentage of Participants with 4 or more DNA-repair Defects with Metastatic Prostate Cancer as an Estimate for Prevalence
  • Percentage of Participants who Meet Biomarker Eligibility Criteria for Other Niraparib Interventional Studies
Secondary Outcome:
  • Percentage of Participants with 4 or more DNA-repair defects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and with Metastatic Hormone Sensitive PC (HSPC) as an Estimate for Prevalence
  • Percentage of Participants with 1 or more DNA-repair defects with Metastatic Prostate Cancer as an Estimate for Prevalence

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer